Compare AUPH & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUPH | VCEL |
|---|---|---|
| Founded | 1993 | 1989 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2014 | 1996 |
| Metric | AUPH | VCEL |
|---|---|---|
| Price | $15.60 | $34.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $17.25 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 1.1M | 666.3K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | 60.00 |
| EPS | ★ 2.07 | 0.32 |
| Revenue | ★ $283,055,000.00 | $276,259,000.00 |
| Revenue This Year | $16.53 | $19.10 |
| Revenue Next Year | $16.24 | $17.95 |
| P/E Ratio | ★ $7.48 | $101.75 |
| Revenue Growth | ★ 20.38 | 16.45 |
| 52 Week Low | $6.83 | $28.95 |
| 52 Week High | $16.54 | $45.97 |
| Indicator | AUPH | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 63.33 | 53.23 |
| Support Level | $14.56 | $30.41 |
| Resistance Level | $16.28 | $34.34 |
| Average True Range (ATR) | 0.52 | 1.76 |
| MACD | 0.15 | 0.26 |
| Stochastic Oscillator | 99.72 | 77.58 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.